LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
about
Prostaglandin E2 signals through PTGER2 to regulate sclerostin expressionControl of the SOST bone enhancer by PTH using MEF2 transcription factorsLrp5 functions in bone to regulate bone massWnt/beta-catenin signaling: components, mechanisms, and diseasesSclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesWnts talking with the TGF-β superfamily: WISPers about modulation of osteoarthritisWNT signaling in bone development and homeostasisCharacterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATIONStructural and Functional Studies of LRP6 Ectodomain Reveal a Platform for Wnt SignalingWnt signaling in bone and muscleRegulation of Wnt/β-catenin signaling within and from osteocytesDissecting molecular differences between Wnt coreceptors LRP5 and LRP6The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healingMutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibitionNon-canonical Wnt signaling and N-cadherin related beta-catenin signaling play a role in mechanically induced osteogenic cell fate.Promising bone-related therapeutic targets for rheumatoid arthritis.Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.Bone mass is inversely proportional to Dkk1 levels in mice.Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblastsHuman Dickkopf-1 (huDKK1) protein: characterization of glycosylation and determination of disulfide linkages in the two cysteine-rich domains.Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease.Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: applications in mice with bone property altering Lrp5 mutationsThe impact of low-magnitude high-frequency vibration on fracture healing is profoundly influenced by the oestrogen status in mice.Functional analysis of disease-associated polymorphism LRP5.Q89RIdentification of the first deletion in the LRP5 gene in a patient with autosomal dominant osteopetrosis type IAutocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In VivoCan we safely target the WNT pathway?Wnt signaling and orthopedics, an overviewRelevance of Wnt signaling for osteoanabolic therapy.LRP6 in mesenchymal stem cells is required for bone formation during bone growth and bone remodeling.Osteoanabolics.The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signalingMolecular and cellular mechanisms of the anabolic effect of intermittent PTHExpression of sclerostin in the developing zebrafish (Danio rerio) brain and skeleton.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro
P2860
Q21560844-D7FFE9BA-8C19-4552-8A16-A22DEBD6E26EQ24337339-43C9575E-2E9B-4359-A431-E32ED8A3B89FQ24615653-6B73E5CF-CCEF-4765-9C7E-6FF82094BA77Q24630938-4AB0778F-95A7-400E-8DCD-F341965959D7Q26744599-6D480D51-A16E-47CE-BFC8-274083A90CFEQ26775922-DC9457DB-C0F6-462C-87F9-97FF771C1B2EQ27008570-2A8AA315-F602-448A-9DA5-8011B8F35D19Q27653715-99E4C394-27A7-4DA1-B519-9281F0AC086BQ27675070-D9DB6EF6-E70C-49B9-A366-578CF9B0DA64Q27687077-E64204E9-7605-4093-8904-CFFE7B415444Q28286814-3582698F-E058-49BB-AAA8-BB4FA00A08B0Q28476670-8FCA226A-B45D-47D2-AE13-CC8124FF63B6Q28512113-F08165D9-037D-4BB6-AEC8-CCE8990F3A44Q28535490-9D4FBF52-FF8A-4809-AFAB-DCD6EFE41C63Q33436209-13CEE92A-A51A-45D3-99C0-02D6BC984514Q33554023-B03BB0DB-69AB-418E-98C3-302D84397DE0Q33564617-EAAB68D0-A11B-4B40-A09C-1070F6E7AB1FQ33570529-9439251E-B63C-4369-A13F-DC50FE5176B7Q33659925-C33F5B54-F19C-4D63-9E31-35D589DEB89EQ33834902-5AB5541E-0DF3-432B-BD9B-3368545C5A91Q33895465-F3C7DF70-CB5B-45B2-AC66-811A028F7FC7Q33976893-D4638A2E-8A59-422B-8234-7061C793354AQ34036439-E1FB3932-CC12-4F75-ABDC-990BAA697A2BQ34181023-EE670AC7-E1A4-4C69-8E39-413679A0F5ACQ34225781-4C2EAA11-FAA2-4549-8493-9D2C01D89668Q34647373-186DAD3D-1CB5-4CAE-A681-4B670AC7D780Q34818364-F17130AA-5908-4AC5-A8C0-B4E1F0C11F94Q34848967-578C1C4C-57C0-4AA0-8F9F-E4E2E1B94220Q35145935-956DFC58-50C6-456E-8D68-CF319F9D63C5Q35251049-17182AC6-4E84-40FC-B151-F6478D9C096FQ35586766-41383B9D-8C40-4CFA-B285-AAD1FD249E0BQ35591995-B55202B7-87B2-4244-A2F2-326283921B4BQ35605991-376AF721-EA5E-4683-BA5C-D18E117CCD29Q35673905-0A341770-42FF-4E6B-804D-82D3EABA44A7Q35755193-5189C1CE-70C6-4881-90DE-B3932D91D657Q35967742-FA658BA9-68BD-44A2-9498-EEE0445E63BEQ35970905-C9F8146C-E1B7-425A-BAE1-165AEC6BAB31Q36016775-D3DB028F-A3B8-4BB2-A703-5996C8A5AB07Q36213693-10079869-2187-4C41-92DF-CFB3BBE1CC39Q36256294-4F2AD2C8-677E-4894-9257-61BD68880952
P2860
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
LRP5 mutations linked to high ...... inding and inhibition by SOST.
@en
type
label
LRP5 mutations linked to high ...... inding and inhibition by SOST.
@en
prefLabel
LRP5 mutations linked to high ...... inding and inhibition by SOST.
@en
P2860
P356
P1476
LRP5 mutations linked to high ...... inding and inhibition by SOST.
@en
P2093
Mikhail V Semenov
P2860
P304
38276-38284
P356
10.1074/JBC.M609509200
P407
P577
2006-10-19T00:00:00Z